This independence between phases and checkpoints has implications for cancer treatment because many cancer drugs directly target different aspects of the cell cycle; for example, CDK4/6 inhibitors block progression out of G1 phase11, while the nucleoside analog gemcitabine activates the DNA damage checkpoint by targeting DNA synthesis during Sphase12. Here, CDK4 is linked to cancer.